KINETICS OF PERIPHERAL BLOOD CD34-POSITIVE CELLS AND THE OPTIMUM TIMING FOR HARVESTING PERIPHERAL BLOOD STEM CELLS DURING BEP CHEMOTHERAPY IN PATIENTS WITH TESTICULAR GERM CELL TUMOR

DOI PubMed 1 Citations 15 References Open Access

Bibliographic Information

Other Title
  • 精巣腫瘍に対するBEP療法施行中の末梢血CD34陽性細胞の推移と末梢血幹細胞採取時期の検討

Search this article

Description

(Purpose) Recently, high-dose chemotherapy with peripheral blood stem cell (PBSC) rescue has been developed for poor risk testicular germ cell cancer. In this study, we investigated the optimum timing for harvesting PBSCs with the use of bleomycin + etoposide + cisplatin (BEP) chemotherapy, which is a well known first-line regimen for the testicular cancer.<br>(Material and Method) Peripheral blood CD34-positive cell ratios were measured during a total of 10 courses of BEP chemotherapy in 6 patients with metastatic germ cell cancer between 1996 and 1998. We performed 4 apheresis in 3 patients during this period. Recombinant human granulocytecolony stimulating factor (rhG-CSF) was administrated from the day on which the neutrophil count decreased less than 1, 000/μl.<br>(Results) The peripheral blood CD34-positive cell ratios became maximum (3.0-24.6% ; average 10.0%) on the day 18 to 21 (median day 19) of BEP chemotherapy with rhG-CSF administration. The maximum ratios of peripheral blood CD34 positive cells were achieved when the number of leukocyte were 6, 880-23, 600/μl and exceeded 6, 000/μl after the 18th day of BEP chemotherapy. The average number of collected CD34 positive cells was 9.5×106/kg at a single apheresis, and 12.6×106/kg per patient.<br>(Conclusion) Efficient hematopoietic progenitor cells were mobilized by BEP chemotherapy with rhG-CSF administration on first-line setting. Our results suggest that the optimum timing of PBSCs harvest is the day when the numbers of leukocyte exceed 6, 000/μl after the 18th day of BEP chemotherapy and the following day.

Journal

Citations (1)*help

See more

References(15)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top